Phosphatidylethanolamine N-methyltransferase: A Potential Drug Target and Biomarker

Target Name: PEMT

NCBI ID: G10400

PEMT

Phosphatidylethanolamine N-methyltransferase: A Potential Drug Target and Biomarker

Phosphatidylethanolamine N-methyltransferase (PEMT) is a gene that encodes a protein involved in cell signaling pathways. The protein is a key enzyme in the phosphatidylcholine (phospholipid) synthesis pathway, which is a critical pathway for the development and maintenance of cellular organelles , including the brain. PEMT is an enzyme that catalyzes the transfer of a phosphate group from a phospholipid molecule to another phospholipid molecule. This transfer of a phosphate group creates a covalent bond between the phospholipids, which is the foundation of cellular signaling.

PEMT is a protein that is expressed in many different cell types, including neurons, muscle cells, and blood vessels. It is also a potent drug target, with several studies having identified PEMT as a potential therapeutic target for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the key reasons for the potential of PEMT as a drug target is its involvement in several key signaling pathways. PEMT is involved in the regulation of cellular signaling by creating covalent bonds between phospholipid molecules. This regulation of signaling pathways is critical for the development and maintenance of cellular organelles, including the brain.

In addition to its involvement in cellular signaling, PEMT is also a potent protein that can be targeted by small molecules. Several studies have shown that small molecules can be used to inhibit the activity of PEMT, which could lead to the inhibition of cellular signaling pathways . This suggests that PEMT could be an attractive target for small molecules that are being developed as potential therapeutic drugs.

Another reason for the potential of PEMT as a drug target is its expression in many different cell types. This makes it a potentially attractive target for drugs that can affect cellular signaling in a wide variety of cell types, rather than being limited to a specific type of cancer or neurodegenerative disease.

In addition to its potential as a drug target, PEMT is also a potential biomarker for several diseases. The phosphatidylcholine synthesis pathway is a critical pathway for the development and maintenance of cellular organelles, including the brain. Therefore, alterations in the levels of PEMT activity or the levels of phospholipid synthesis can be potential biomarkers for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Overall, PEMT is a protein that is involved in several key cellular signaling pathways and has the potential to be a drug target or biomarker for several diseases. Further research is needed to fully understand the role of PEMT in cellular signaling and its potential as a therapeutic target or biomarker.

Protein Name: Phosphatidylethanolamine N-methyltransferase

Functions: Catalyzes the three sequential steps of the methylation pathway for the biosynthesis of phosphatidylcholine, a critical and essential component for membrane structure (PubMed:12431977, PubMed:15927961). Uses S-adenosylmethionine (S-adenosyl-L-methionine, SAM or AdoMet) as the methyl group donor for the methylation of phosphatidylethanolamine (1,2-diacyl-sn-glycero-3-phosphoethanolamine, PE) to phosphatidylmonomethylethanolamine (1,2-diacyl-sn-glycero-3-phospho-N-methylethanolamine, PMME), PMME to phosphatidyldimethylethanolamine (1,2-diacyl-sn-glycero-3-phospho-N,N-dimethylethanolamine, PDME), and PDME to phosphatidylcholine (1,2-diacyl-sn-glycero-3-phosphocholine, PC), producing S-adenosyl-L-homocysteine in each step (PubMed:12431977, PubMed:15927961). Responsible for approximately 30% of hepatic PC with the CDP-choline pathway accounting for the other 70% (Probable)

The "PEMT Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PEMT comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets